Community-acquired Pneumonia

Outlook for patients with CAP worldwide
 

ZINFORO^® offers an efficacious and potent treatment for patients with CAP.^1,2,*
Consistently active against common causative pathogens, delivering positive outcomes

*REACH was a retrospective, observational study relating to the current treatment practice in 10 European countries (Belgium, France, Germany, Greece, Italy, the Netherlands, Portugal, Spain, Turkey and the United Kingdom).
REACH does not include data specific to ZINFORO^®.
In REACH, ‘initial treatment modification’ was defined as the need for a change in the first-line antibiotic treatment due to insufficient response, adverse reaction, interaction with other drugs, non-suitability of the initial antibiotic based on the results of microbiological tests and changes to, or additions of, new agents in a subsequent line (alone or in combination). Patient death or streamlining (de-escalation of treatment to narrow-spectrum antibiotics upon patient improvement or confirmed microbiological diagnosis) was not included within the definition of initial treatment modification.^5
†There is no experience with ZINFORO^® in the treatment of CAP in the following patient groups: The immunocompromised, patients with severe sepsis/septic shock and severe underlying lung disease; patients with PORT risk Class V, and/or CAP requiring ventilation at presentation, CAP due to MRSA and patients requiring intensive care. Caution is advised when treating such patients.⁸

​​​​​​​CAP, community-acquired pneumonia; cSSTI, complicated skin and soft tissue infection; MoA, mechanism of action; MRSA, methicillin-resistant Staphylococcus aureus; PORT, Pneumonia Patient Outcomes Research Team; REACH, REtrospective Study to Assess the Clinical Management of Patients With Moderate-to-Severe cSSTI or CAP in the Hospital Setting.
 

​​​​​​​References: